EGFR and neoplasm: This makes the tumour more prone to immune evasion and better able to adapt to therapeutic stress, ultimately leading to resistance, rapid disease progression and even histological transformation (e.g., EGFR‐mutant LUAD transforming to SCLC is often accompanied by TP53/RB1 inactivation, significantly worsening prognosis).